Author name: Mike M.

after-ukrainian-testing,-drone-detection-radar-doubles-range-with-simple-software-patch

After Ukrainian testing, drone-detection radar doubles range with simple software patch

As part of its unprovoked invasion, Russia has been firing massed waves of drones and missiles into Ukraine for years, though the tempo has been raised dramatically in recent months. Barrages of 700-plus drones now regularly attack Ukraine during overnight raids. Russia also appears to have upped the ante dramatically by sending at least 19 drones into Poland last night, some of which were shot down by NATO forces.

Many of these drones are Shahed/Geran types built with technology imported from Iran, and they have recently gained the ability to fly higher, making shootdowns more difficult. Given the low cost of the drones (estimates suggest they cost a few tens of thousands of dollars apiece, and many are simply decoys without warheads), hitting them with multimillion-dollar missiles from traditional air-defense batteries makes little sense and would quickly exhaust missile stocks.

So Ukraine has adopted widespread electronic warfare to disrupt control systems and navigation. Drones not forced off their path are fought with mobile anti-aircraft guns, aircraft, and interceptor drones, many launched from mobile fire teams patrolling Ukraine during the night.

For teams like this, early detection of the attack drones is crucial—even seconds matter when it comes to relocating a vehicle and launching a counter drone or aiming a gun. Take too long to get into position and the attack drone overhead has already passed by on the way to its target.

Which brings us to Robin Radar Systems, a Dutch company that initially used radar to detect birds. (Indeed, the name “Robin” is an acronym derived from “Radar OBservation of Bird INtensity.”) This radar technology, good at detecting small flying objects and differentiating them from fauna, has proven useful in Ukraine’s drone war. Last year, the Dutch Ministry of Defence bought 51 mobile Robin Radar IRIS units that could be mounted on vehicles and used by drone defense teams.

After Ukrainian testing, drone-detection radar doubles range with simple software patch Read More »

has-perseverance-found-a-biosignature-on-mars?

Has Perseverance found a biosignature on Mars?


Interpreting the data is tricky because other non-biological processes could account for the findings.

Credit: NASA/JPL-Caltech/MSSS

Last year, we reported on the discovery of an intriguing arrow-shaped rock on Mars by NASA’s Perseverance rover. The rock contained chemical signatures and structures that could have been formed by ancient microbial life. Granted, this was not slam-dunk evidence of past life on Mars, and the results were preliminary, awaiting peer review. But it was an intriguing possibility nonetheless.

Now further analysis and peer review are complete, and there is a new paper, published in the journal Nature, reporting on the findings. It’s still not definitive proof that there was water-based life on Mars billions of years ago, but the results are consistent with a biosignature. It’s just that other non-biological processes would also be consistent with the data, so definitive proof might require analysis of the Martian samples back on Earth. You can watch NASA’s livestream briefing here.

“We have improved our understanding of the geological context of the discovery since [last year], and in the paper, we explore abiotic and biological pathways to the formation of the features that we observe,” co-author Joel Hurowitz, an astrobiologist at Stony Brook University in New York, told Ars. “My hope is that this discovery motivates a whole bunch of new research in laboratory and analog field settings on Earth to try to understand what conditions might give rise to the textures and mineral assemblages we’ve observed. This type of follow on work is exactly what is needed to explore the various biological and abiotic pathways to the formation of the features that we are calling potential biosignatures.”

On February 18, 2021, Perseverance landed in Jezero Crater, a site chosen because rocks resembling a river delta are draped over its rim, indicating that flowing water might have met a lake here in the past. The little rover has multiple cameras for both general imagery and spectral analysis, supplemented by an X-ray instrument. A ground-penetrating radar instrument can reveal layering hidden below the surface; a weather module tracks atmospheric conditions and airborne dust; and a drill on the end of its robotic arm grinds clean spots for analysis. The drill can also core out small cylindrical rock samples.

Mineralogical map of the Martian surface explored by the Perseverance rover.

Mineralogical map of the Martian surface explored by the Perseverance rover. Credit: M. Parente et al./Zenodo 2021

By the end of 2021, Perseverance had identified igneous rocks in the Seitah formation on the crater’s floor, containing the mineral olivine surrounded by pyroxene. This combination is known as a cumulate; olivine crystallizes early and can settle to the bottom of a magma body and accumulate, and it’s a common formation in magma chambers on Earth. Scientists thought that Jezero was once a lake; this was evidence of possible volcanic activity.

An arrow-shaped clue

As Ars Space Editor Eric Berger reported last year, the arrow-shaped rock that caused such a stir last year was collected on July 21, 2024, as the rover explored the Neretva Vallis riverbed. The science team operating Perseverance nicknamed the rock Chevaya Falls and subjected it to multiple scans by the rover’s SHERLOC (Scanning Habitable Environments with Raman & Luminescence for Organics & Chemicals) instrument. Samples were taken from two sites known as Bright Angel and Masonic Temple; the arrow-shaped rock came from Bright Angel.

That analysis revealed  tiny green specks of iron phosphates that have been chemically reduced, as well as iron sulfide minerals, all embedded in mudstone composed of iron minerals, clays, and calcium sulfates. Those distinctive colorful nodules and specks are a smoking gun for certain chemical reactions (known as redox) rather than microbial life itself. On Earth, microbial life can derive energy from these kinds of chemical reactions, so signs of such reactions suggest a plausible source of energy for microbes on Mars. In addition, there are organic chemicals present on the same rock, consistent with some form of life.

This latest paper confirms those initial findings and also concludes that the iron phosphate in the green specks is most likely vivianite, consistent with prior samples taken from the crater’s Onahu site. The nodules and specks seem to have formed under low-temperature conditions and after the deposition of sediment. And the minerals of interest aren’t evenly distributed throughout the mudstone; they are concentrated in specific zones. All of this taken together suggests that these might be biosignatures, per the authors.

So what needs to happen to definitively confirm these are actual signs of previous life on Mars? NASA has a seven-step process for determining whether something can be confirmed as extraterrestrial life. This is known as the CoLD scale, for Confidence of Life Detection. In this case, the detection of these spots on a Martian rock represented just the first of seven steps. Among other steps, scientists must rule out any non-biological possibility and identify other signals to have confidence in off-world life—i.e., solving the so-called “false positive” problem.

For instance, “Analyses of sulfur isotopes can be used to trace the geochemical and biogeochemical pathways that formed sulfate and sulfides,” Janice Bishop (SETI Institute) and Mario Parente (University of Massachusetts Amherst) wrote in an accompanying perspective. “Such analyses would be needed to determine whether ancient microbes participated in the redox reactions that formed these minerals on Mars.”

Michael Wong, an astrobiologist at Carnegie Science who was not involved in the research, told Ars that he appreciated Hurowotiz et al.’s care in not over-hyping their findings and thinks they make a compelling case. Unlike hints of biosignatures on distant exoplanets, he thinks scientists can have confidence in the Mars data. “We’re right up against the rocks, we’re taking spectra of things that we can get up close and personal with,” he said.

The tricky part is in the interpretation of that data. “I think this is consistent with a potential biosignature,” said Wong. “I wouldn’t get too excited, of course, because there could be interesting geological mechanisms for creating these phenomena that we just haven’t thought of yet.”

Chemically reduced nodules of greenish material containing the mineral vivianite are embedded in a matrix of red–brown, oxidized clay mineral. More-complex ‘leopard spot’ features contain vivianite along with a sulfide mineral

Chemically reduced nodules of greenish material containing the mineral vivianite are embedded in a matrix of red-brown, oxidized clay mineral. More complex ‘leopard spot’ features contain vivianite along with a sulfide mineral. Credit: J. Hurowitz et al. 2025

Still cause for skepticism

That said, “I’d love to know a little bit more about what organics were found and in what abundances,” said Wong. “If you can look at the distribution of, say, amino acids or lipids, these building blocks of life, that can be a really important clue as to whether or not it’s actually life that was responsible here. Life is really good at making molecules that function well, and it doesn’t care about making molecules that don’t play into its metabolism and replication cycles. I’d love to know a little bit more about the isotopic ratios of those organic compounds, because life preferentially absorbs lighter isotopes than heavier ones.”

Sara Walker, an astrobiologist at Arizona State University who was not involved in the study, told Ars that analyses like that of Hurowitz et al. “are often targeted at simple metabolic products or reactions that life on Earth is known to mediate, but which are not uniquely diagnostic of life, e.g. can be produced abiotically,” she said. “It is not in general possible to exhaustively rule out all possible abiotic causes, especially in planetary science contexts where we have limited information, as is always the case for Mars data. A convincing biosignature detection would need to be based on detection of a signature of life that has no false positives.”

Much will depend on NASA’s planned Mars Sample Return mission. Returning pristine specimens from Mars to Earth for analysis in ground-based labs has been a top priority for the planetary science community’s decadal survey process. “The Perseverance rover wasn’t designed to make any definitive claims about biosignatures, but only to look for samples that have the most intriguing clues and would be the most interesting to bring back to Earth so that we can analyze it with all of the fancy instrumentation here,” said Wong.

Getting those samples back has turned out to be a lot more challenging than NASA thought. In 2023, an independent review found ballooning costs and delays threatened the mission’s viability. The effort would likely cost NASA between $8 billion and $11 billion, and the launch would be delayed at least two years until 2030, with samples getting back to Earth a few years later, the review board concluded. NASA put out a call to industry in April of this year to propose ideas on how to return the Mars rocks to Earth for less than $11 billion and before 2040, selecting seven companies to conduct more detailed studies.

“Ultimately, I suspect that we’ll find that there are ways that you can make them under very specific abiotic—perhaps at high temperature—and biological conditions, and we’ll end up at a point where the sample will need to come home so that we can study it and make the final determination for what process made these features,” said Hurowitz. “But the follow-on work will provide testable hypotheses that can guide the examination of the Sapphire Canyon core sample we collected from the Bright Angel formation even before it comes back to Earth.”

According to Walker, while sample return would be ideal, it may not be critical to detection of extraterrestrial biosignatures, or even provide a conclusive determination in the present case. For these kinds of signatures, “There will always be some doubt, whether studied here on Earth or elsewhere,” Walker said. “There are lots of clever means to doing better science for biosignatures on other worlds. I would focus on ones that do not have false positives. But this is a direction that is very new in the field.” Her own research involves using assembly theory and mass spectrometry to identify molecules that are too complex to form abiotically.

Those alternatives might be the best course given the current state of science funding in the US. “In planetary science and astrobiology, the funding cuts to the NASA science mission directorate makes it really difficult to imagine a near future in which we can actually do the analysis,” said Wong. “We need to determine whether or not these ancient Mars rocks do or do not contain signs of alien life. We’re leaving on the doorstep this really intriguing question that we can answer if we brought the samples back to Earth, but we simply aren’t going to. We could be on the steps of a golden age of astrobiology if only we had the willpower to do it.”

DOI: Nature, 2025. 10.1038/s41586-025-09413-0  (About DOIs).

Photo of Jennifer Ouellette

Jennifer is a senior writer at Ars Technica with a particular focus on where science meets culture, covering everything from physics and related interdisciplinary topics to her favorite films and TV series. Jennifer lives in Baltimore with her spouse, physicist Sean M. Carroll, and their two cats, Ariel and Caliban.

Has Perseverance found a biosignature on Mars? Read More »

accessory-maker-will-pay-nintendo-after-showing-illicit-switch-2-mockups-at-ces

Accessory maker will pay Nintendo after showing illicit Switch 2 mockups at CES

Nintendo also accused Genki of “extensive use of Nintendo trademarks” in association with their unlicensed products, a move that “exploit[ed] and appropriate[d] for [Genki] the public goodwill associated with… Nintendo Switch marks.”

The Switch 2 mockup Genki showed in a CES video ended up matching very closely with the final console as released.

The Switch 2 mockup Genki showed in a CES video ended up matching very closely with the final console as released. Credit: Genki

The lawsuit also dealt in part with conflicting reports that Genki may have had “unauthorized, illegal early access to the Nintendo Switch 2,” as Nintendo put it. Media reports around CES quoted Genki representatives asserting that their 3D-printed case mockup was based on early access to a real Switch 2 console. But the company later publicly backtracked, writing on social media that “we do not own or possess a black market console, as some outlets have suggested.”

In their settlement, Nintendo and Genki simply note that “Genki represents and attests that it didn’t obtain any unreleased Nintendo property or documents before the system’s official reveal.”

The public settlement document doesn’t go into detail on the confidential “payment in an agreed-upon amount” that Genki will make to Nintendo to put this matter to rest. But the settlement outlines how Genki is barred from referencing Nintendo trademarks or even parody names like “Glitch” and “Glitch 2” in its future marketing. Under the settlement, packaging for Genki accessories also has to “make clear to consumers Genki’s status as an unlicensed accessory manufacturer” and not mimic the color scheme of official Switch 2 hardware.

Accessory maker will pay Nintendo after showing illicit Switch 2 mockups at CES Read More »

in-court-filing,-google-concedes-the-open-web-is-in-“rapid-decline”

In court filing, Google concedes the open web is in “rapid decline”

Advertising and the open web

Google objects to this characterization. A spokesperson calls it a “cherry-picked” line from the filing that has been misconstrued. Google’s position is that the entire passage is referring to open-web advertising rather than the open web itself. “Investments in non-open web display advertising like connected TV and retail media are growing at the expense of those in open web display advertising,” says Google.

If we assume this is true, it doesn’t exactly let Google off the hook. As AI tools have proliferated, we’ve heard from Google time and time again that traffic from search to the web is healthy. When people use the web more, Google makes more money from all those eyeballs on ads, and indeed, Google’s earnings have never been higher. However, Google isn’t just putting ads on websites—Google is also big in mobile apps. As Google’s own filings make clear, in-app ads are by far the largest growth sector in advertising. Meanwhile, time spent on non-social and non-video content is stagnant or slightly declining, and as a result, display ads on the open web earn less.

So, whether Google’s wording in the filing is meant to address the web or advertising on the web may be a distinction without a difference. If ads on websites aren’t making the big bucks, Google’s incentives will undoubtedly change. While Google says its increasingly AI-first search experience is still consistently sending traffic to websites, it has not released data to show that. If display ads are in “rapid decline,” then it’s not really in Google’s interest to continue sending traffic to non-social and non-video content. Maybe it makes more sense to keep people penned up on its platform where they can interact with its AI tools.

Of course, the web isn’t just ad-supported content—Google representatives have repeatedly trotted out the claim that Google’s crawlers have seen a 45 percent increase in indexable content since 2023. This metric, Google says, shows that open web advertising could be imploding while the web is healthy and thriving. We don’t know what kind of content is in this 45 percent, but given the timeframe cited, AI slop is a safe bet.

If the increasingly AI-heavy open web isn’t worth advertisers’ attention, is it really right to claim the web is thriving as Google so often does? Google’s filing may simply be admitting to what we all know: the open web is supported by advertising, and ads increasingly can’t pay the bills. And is that a thriving web? Not unless you count AI slop.

In court filing, Google concedes the open web is in “rapid decline” Read More »

supreme-court-chief-justice-lets-trump-fire-ftc-democrat,-at-least-for-now

Supreme Court Chief Justice lets Trump fire FTC Democrat, at least for now

1935 Supreme Court is key precedent

The key precedent in the case is Humphrey’s Executor v. United States, a 1935 ruling in which the Supreme Court unanimously held that the president can only remove FTC commissioners for inefficiency, neglect of duty, or malfeasance in office. Trump’s termination notices to Slaughter and Bedoya said they were being fired simply because their presence on the commission “is inconsistent with my Administration’s priorities.”

The Trump administration argues that Humphrey’s Executor shouldn’t apply to the current version of the FTC because it exercises significant executive power. But the appeals court, in a 2-1 ruling, said “the present-day Commission exercises the same powers that the Court understood it to have in 1935 when Humphrey’s Executor was decided.”

“The government has no likelihood of success on appeal given controlling and directly on point Supreme Court precedent,” the panel majority said.

But while the government was found to have no likelihood of success in the DC Circuit appeals court, its chances are presumably much better in the Supreme Court. The Supreme Court previously stayed District Court decisions in cases involving Trump’s removal of Democrats from the National Labor Relations Board, the Merit Systems Protection Board, and the Consumer Product Safety Commission.

In a 2020 decision involving the Consumer Financial Protection Bureau, the court said in a footnote that its 1935 “conclusion that the FTC did not exercise executive power has not withstood the test of time.” If the Supreme Court ultimately rules in favor of Trump, it could throw out the Humphrey’s Executor ruling or clarify it in a way that makes it inapplicable to the FTC.

But Humphrey’s Executor is still a binding precedent, Slaughter’s opposition to the administrative stay said. “This Court should not grant an administrative stay where the court below simply ‘follow[ed] the case which directly controls,’ as it was required to do,” the Slaughter filing said.

Supreme Court Chief Justice lets Trump fire FTC Democrat, at least for now Read More »

who-can-get-a-covid-vaccine—and-how?-it’s-complicated.

Who can get a COVID vaccine—and how? It’s complicated.


We’re working with a patchwork system, and there are a lot of gray areas.

Vaccinations were available at CVS in Huntington Park, California, on August 28, 2024. Credit: Getty | Christina House

As fall approaches and COVID cases tick up, you might be thinking about getting this season’s COVID-19 vaccine. The annually updated shots have previously been easily accessible to anyone over 6 months of age. Most people could get them at no cost by simply walking into their neighborhood pharmacy—and that’s what most people did.

However, the situation is much different this year with an ardent anti-vaccine activist, Robert F. Kennedy Jr., as the country’s top health official. Since taking the role, Kennedy has worked diligently to dismantle the country’s premier vaccination infrastructure, as well as directly hinder access to lifesaving shots. That includes restricting access to COVID-19 vaccines—something he’s done by brazenly flouting all standard federal processes while providing no evidence-based reasoning for the changes.

How we got here

In late May, Kennedy unilaterally decided that all healthy children and pregnant people should no longer have access to the shots. He announced the unprecedented change not through official federal channels, but via a video posted on Elon Musk’s X platform. Top vaccine and infectious disease officials at the Centers for Disease Control and Prevention—which sets federal vaccination recommendations—said they also learned of the change via X.

Medical experts—particularly the American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists (ACOG)—immediately slammed the change, noting that data continues to indicate pregnant women and children under age 2 are particularly vulnerable to severe COVID-19. Both medical groups have since released their own vaccination guidance documents that uphold COVID-19 vaccine recommendations for those patient groups. (AAP here, ACOG here)

Nevertheless, in line with Kennedy, officials at the Food and Drug Administration signaled that they would take the unprecedented, unilateral step of changing the labels on the vaccines to limit who could get them—in this case, people 65 and over, and children and adults with health conditions that put them at risk of severe COVID-19. Kennedy’s FDA underlings—FDA Commissioner Martin Makary and top vaccine regulator, Vinay Prasad—laid out the plans alongside a lengthy list of health conditions in a commentary piece published in the New England Journal of Medicine. The list includes pregnancy—which is evidence-based, but odd, since it conflicts with Kennedy.

What was supposed to happen

When there isn’t a zealous anti-vaccine activist personally directing federal vaccine policy, US health agencies have a thorough, transparent protocol for approving and recommending vaccinations. Generally, it starts with the FDA, which has both its own scientists and a panel of outside expert advisors to review safety and efficacy data submitted by a vaccine’s maker. The FDA’s advisory committee—the Vaccines and Related Biological Products Advisory Committee (VRBPAC)—then holds a completely public meeting to review, analyze, and discuss the data. They make a recommendation on a potential approval and then the FDA commissioner can decide to sign off, typically in accordance with internal experts.

Resulting FDA approvals or authorizations are usually broad, basically covering people who could safely get the vaccine. The specifics of who should get the vaccine fall to the CDC.

Once the FDA approves or authorizes a vaccine, the CDC has a similar evaluation process. Internal experts review all the data for the vaccine, plus the epidemiological and public health data to assess things like disease burden, populations at risk, resource access, etc. A committee of outsides expert advisors do the same—again in a totally transparent public meeting that is livestreamed with all documents and presentations available on the CDC’s website.

That committee, the Advisory Committee on Immunization Practices (ACIP), then makes recommendations to the CDC about how the shots should be used. These recommendations can provide nuanced clinical guidance on exactly who should receive a vaccine, when, in what scenarios, and in what time series, etc. The recommendations may also be firm or soft—e.g., some people should get a vaccine, while others may get the vaccine.

The CDC director then decides whether to adopt ACIP’s recommendations (the director usually does) and updates the federal immunization schedules accordingly. Those schedules set clinical standards for immunizations, including routine childhood vaccinations, nationwide. Once a vaccine recommendation makes it to the ACIP-guided federal immunization schedules, private health insurance companies are required to cover those recommended vaccinations at no cost to members. And—a key catch for this year—19 states tie ACIP vaccine recommendations to pharmacists’ ability to independently administer vaccines.

What actually happened

Days after Kennedy’s X announcement of COVID-19 vaccine restrictions in late May, the CDC changed the federal immunization schedules. The recommendation for a COVID-19 shot during pregnancy was removed. But, for healthy children 6 months to 17 years, the CDC diverged from Kennedy slightly. The updated schedule doesn’t revoke access outright; instead, it now says that healthy children can get the shots if there is shared decision-making with the child’s doctor, that is, if the parent/child wants to get the vaccine and the doctor approves. ACIP was not involved in any of these changes.

On August 27, the FDA followed through with its plans to change the labels on COVID-19 vaccines, limiting access to people who are 65 and older and people who have an underlying condition that puts them at high risk of severe COVID-19.

FDA’s advisory committee, VRBPAC, met in late May, just a few days after FDA officials announced their plans to restrict COVID-19 vaccine access. The committee was not allowed to discuss the proposed changes. Instead, it was limited to discussing the SARS-CoV-2 strain selection for the season, and questions about the changes were called “off topic” by an FDA official.

ACIP, meanwhile, has not met to discuss the use of the updated COVID-19 vaccines for the 2025–2026 season. Last year, ACIP met and set the 2024–2025 COVID-19 shot recommendations in June. But, instead, in June of this year, Kennedy fired all 17 members of ACIP, falsely claiming members were rife with conflicts of interest. He quickly repopulated ACIP with anti-vaccine allies who are largely unqualified and some of whom have been paid witnesses in lawsuits against vaccine makers, a clear conflict of interest. While Kennedy is reportedly working to pack more anti-vaccine activists onto ACIP, the committee is scheduled to meet and discuss the COVID-19 vaccine on September 18 and 19. The committee will also discuss other vaccines.

Outside medical and public health experts view ACIP as critically compromised and expect it will further restrict access to vaccines.

With this set of events, COVID-19 vaccine access is in disarray. Here’s what we do and don’t know about access.

Getting a vaccine

FDA vaccine criteria

Prior to Kennedy, COVID-19 vaccines were available to all people ages 6 months and up. But that is no longer the case. The current FDA approvals are as follows:

Pfizer’s mRNA COVID-19 vaccine (COMIRNATY) is only available to people:

  • 65 years of age and older, or
  • 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Moderna’s mRNA COVID-10 vaccine (SPIKEVAX) is only available to people:

  • 65 years of age and older, or
  • 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Novavax’s protein subunit COVID-19 vaccine NUVAXOVID is only available to people:

  • 65 years of age and older, or
  • 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Who can get a COVID-19 vaccine and where now depends on a person’s age, underlying conditions, and the state they reside in.

States-based restrictions

The fact that ACIP has not set recommendations for the use of 2025–2026 COVID-19 vaccines means vaccine access is a messy patchwork across the country. As mentioned above, 19 states link pharmacists’ ability to independently provide COVID-19 vaccines to ACIP recommendations. Without those recommendations, pharmacies in those states may not be able to administer the vaccines at all, or only provide them with a doctor’s prescription—even for people who fit into the FDA’s criteria.

Last week, The New York Times reported that CVS and Walgreens, the country’s largest pharmacy chains, were either not providing vaccines or requiring prescriptions in 16 states. And the list of 16 states where CVS had those restrictions was slightly different than where Walgreens had them, likely due to ambiguities in state-specific regulations.

The National Alliance of State Pharmacy Associations (NASPA) and the American Pharmacists Association (APhA) have a state-by-state overview of pharmacist vaccination authority regulations here.

For people meeting the FDA criteria

In the 31 states that allow for broader pharmacist vaccination authority, people meeting FDA’s criteria (65 years and older, and people with underlying conditions), should be able to get the vaccine at a pharmacy like usual. And once ACIP sets recommendations later this month—assuming the committee doesn’t restrict access further—people in those groups should be able to get them at pharmacies in the remaining states, too.

Proving underlying conditions

People under 65 with underlying health conditions who want to get their COVID-19 shot at a pharmacy will likely have to do something to confirm their eligibility.

Brigid Groves, APhA’s vice president of professional affairs and the organization’s expert on vaccine policy, told Ars that the most likely scenario is that people will have to fill out forms prior to vaccination, indicating the conditions they have that make them eligible, a process known as self-attestation. This is not unusual, Groves noted. Other vaccinations require such self-attestation of conditions, and for years, this has been sufficient for pharmacists to administer vaccines and for insurance policies to cover those vaccinations, she said.

“APhA is a strong supporter of that patient self-attestation, recognizing that patients have a very good grasp of their medical conditions,” Groves said.

For people who don’t meet the FDA criteria

There are a lot of reasons why healthy children and adults outside the FDA’s criteria may still want to get vaccinated: Maybe they are under the age of 2, an age that is, in fact, still at high risk of severe COVID-19; maybe they live or work with vulnerable people, such as cancer patients, the elderly, or immunocompromised; or maybe they just want to avoid a crummy respiratory illness that they could potentially pass on to someone else.

For these people, regardless of what state they are in, getting the vaccine would mean a pharmacist or doctor would have to go “off-label” to provide it.

“It’s very gray on how a pharmacist may proceed in that scenario,” Groves told Ars. Going off-label could open pharmacists up to liability concerns, she said. And even if a patient can obtain a prescription for an off-label vaccine, that still may not be enough to allow a pharmacist to administer the vaccine.

“Pharmacists have something called ‘corresponding responsibility,’ Groves explained. “So even if a physician, or a nurse practitioner, or whomever may send a prescription over for that vaccine, that pharmacist still has that responsibility to ensure this is the right medication, for the right patient, at the right time, and that they’re indicated for it,” she said. So, it would still be going outside what they’re technically authorized to do.

Doctors, on the other hand, can administer vaccines off-label, which they might do if they choose to follow guidance from medical organizations like AAP and ACOG, or if they think it’s best for their patient. They can do this without any heightened professional liability, contrary to some suggestions Kennedy has made (doctors prescribe things off-label all the time). But, people may have to schedule an appointment with their doctor and convince them to provide the shot—a situation far less convenient than strolling into a local pharmacy. Also, since pharmacies have provided the vast majority of COVID-19 vaccines so far, some doctors’ offices may not have them on hand.

Pregnancy

It’s unclear if pregnancy still falls under the FDA’s criteria for a high-risk condition. It was included in the list that FDA officials published in May. However, the agency did not make that list official when it changed the vaccine labels last month. Some experts have suggested that, in this case, the qualifying high-risk conditions default to the CDC’s existing list of high-risk conditions, which includes pregnancy. But it’s not entirely clear.

In addition, with Kennedy’s previous unilateral change to the CDC’s immunization schedule—which dropped the COVID-19 vaccine recommendation during pregnancy—pregnant people could still face barriers to getting the vaccine in the 19 states that link pharmacist authorization to ACIP recommendations. That could change if ACIP reverses Kennedy’s restriction when the committee meets later this month, but that may be unlikely.

Insurance coverage

It’s expected that insurance companies will continue to cover the full costs of COVID-19 vaccines for people who meet the FDA criteria. For off-label use, it remains unclear.

Groves noted that in June, AHIP, the trade organization for health insurance providers, put out a statement suggesting that it would continue to cover vaccines at previous levels.

“We are committed to ongoing coverage of vaccines to ensure access and affordability for this respiratory virus season. We encourage all Americans to talk to their health care provider about vaccines,” the statement reads.

However, Groves was cautious about how to interpret that. “At the end of the day, on the claims side, we’ll see how that pans out,” she said.

Rapidly evolving access

While the outcome of the ACIP meeting on September 18 and 19 could alter things, a potentially bigger source of change could be actions by states. Already, there have been rapid responses with states changing their policies to ensure pharmacists can provide vaccines, and states making alliances with other states to provide vaccine recommendations and vaccines themselves.

Photo of Beth Mole

Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes.

Who can get a COVID vaccine—and how? It’s complicated. Read More »

“first-of-its-kind”-ai-settlement:-anthropic-to-pay-authors-$1.5-billion

“First of its kind” AI settlement: Anthropic to pay authors $1.5 billion

Authors revealed today that Anthropic agreed to pay $1.5 billion and destroy all copies of the books the AI company pirated to train its artificial intelligence models.

In a press release provided to Ars, the authors confirmed that the settlement is “believed to be the largest publicly reported recovery in the history of US copyright litigation.” Covering 500,000 works that Anthropic pirated for AI training, if a court approves the settlement, each author will receive $3,000 per work that Anthropic stole. “Depending on the number of claims submitted, the final figure per work could be higher,” the press release noted.

Anthropic has already agreed to the settlement terms, but a court must approve them before the settlement is finalized. Preliminary approval may be granted this week, while the ultimate decision may be delayed until 2026, the press release noted.

Justin Nelson, a lawyer representing the three authors who initially sued to spark the class action—Andrea Bartz, Kirk Wallace Johnson, and Charles Graeber—confirmed that if the “first of its kind” settlement “in the AI era” is approved, the payouts will “far” surpass “any other known copyright recovery.”

“It will provide meaningful compensation for each class work and sets a precedent requiring AI companies to pay copyright owners,” Nelson said. “This settlement sends a powerful message to AI companies and creators alike that taking copyrighted works from these pirate websites is wrong.”

Groups representing authors celebrated the settlement on Friday. The CEO of the Authors’ Guild, Mary Rasenberger, said it was “an excellent result for authors, publishers, and rightsholders generally.” Perhaps most critically, the settlement shows “there are serious consequences when” companies “pirate authors’ works to train their AI, robbing those least able to afford it,” Rasenberger said.

“First of its kind” AI settlement: Anthropic to pay authors $1.5 billion Read More »

microsoft-open-sources-bill-gates’-6502-basic-from-1978

Microsoft open-sources Bill Gates’ 6502 BASIC from 1978

On Wednesday, Microsoft released the complete source code for Microsoft BASIC for 6502 Version 1.1, the 1978 interpreter that powered the Commodore PET, VIC-20, Commodore 64, and Apple II through custom adaptations. The company posted 6,955 lines of assembly language code to GitHub under an MIT license, allowing anyone to freely use, modify, and distribute the code that helped launch the personal computer revolution.

“Rick Weiland and I (Bill Gates) wrote the 6502 BASIC,” Gates commented on the Page Table blog in 2010. “I put the WAIT command in.”

For millions of people in the late 1970s and early 1980s, variations of Microsoft’s BASIC interpreter provided their first experience with programming. Users could type simple commands like “10 PRINT ‘HELLO'” and “20 GOTO 10” to create an endless loop of text on their screens, for example—often their first taste of controlling a computer directly. The interpreter translated these human-readable commands into instructions that the processor could execute, one line at a time.

The Commodore PET (Personal Electronic Transactor) was released in January 1977 and used the MOS 6502 and ran a variation of Microsoft BASIC. Credit: SSPL/Getty Images

At just 6,955 lines of assembly language—Microsoft’s low-level 6502 code talked almost directly to the processor. Microsoft’s BASIC squeezed remarkable functionality into minimal memory, a key achievement when RAM cost hundreds of dollars per kilobyte.

In the early personal computer space, cost was king. The MOS 6502 processor that ran this BASIC cost about $25, while competitors charged $200 for similar chips. Designer Chuck Peddle created the 6502 specifically to bring computing to the masses, and manufacturers built variations of the chip into the Atari 2600, Nintendo Entertainment System, and millions of Commodore computers.

The deal that got away

In 1977, Commodore licensed Microsoft’s 6502 BASIC for a flat fee of $25,000. Jack Tramiel’s company got perpetual rights to ship the software in unlimited machines—no royalties, no per-unit fees. While $25,000 seemed substantial then, Commodore went on to sell millions of computers with Microsoft BASIC inside. Had Microsoft negotiated a per-unit licensing fee like they did with later products, the deal could have generated tens of millions in revenue.

The version Microsoft released—labeled 1.1—contains bug fixes that Commodore engineer John Feagans and Bill Gates jointly implemented in 1978 when Feagans traveled to Microsoft’s Bellevue offices. The code includes memory management improvements (called “garbage collection” in programming terms) and shipped as “BASIC V2” on the Commodore PET.

Microsoft open-sources Bill Gates’ 6502 BASIC from 1978 Read More »

lull-in-falcon-heavy-missions-opens-window-for-spacex-to-build-new-landing-pads

Lull in Falcon Heavy missions opens window for SpaceX to build new landing pads

SpaceX’s goal for this year is 170 Falcon 9 launches, and the company is on pace to come close to this target. Most Falcon 9 launches carry SpaceX’s own Starlink broadband satellites into orbit. The FAA’s environmental approval opens the door for more flights from SpaceX’s busiest launch pad.

But launch pad availability is not the only hurdle limiting how many Falcon 9 flights can take off in a year. There’s also the rate of production for Falcon 9 upper stages, which are new on each flight, and the time it takes for each vessel in SpaceX’s fleet of drone ships (one in California, two in Florida) to return to port with a recovered booster and redeploy back to sea again for the next mission. SpaceX lands Falcon 9 boosters on offshore drone ships after most of its launches and only brings the rocket back to an onshore landing on missions carrying lighter payloads to orbit.

When a Falcon 9 booster does return to landing on land, it targets one of SpaceX’s recovery zones at military-run spaceports in Florida and California. SpaceX’s landing zone at Vandenberg Space Force Base in California is close to the Falcon 9 launch pad there.

The Space Force wants SpaceX, and potentially other future reusable rocket companies, to replicate the side-by-side launch and landing pads at Cape Canaveral.

To do that, the FAA also gave the green light Wednesday for SpaceX to construct and operate a new rocket landing zone at SLC-40 and conduct up to 34 first-stage booster landings there each year. The landing zone will consist of a 280-foot diameter concrete pad surrounded by a 60-foot-wide gravel apron. The landing zone’s broadest diameter, including the apron, will measure 400 feet.

The location of SpaceX’s new rocket landing pad is shown with the red circle, approximately 1,000 feet northeast of the Falcon 9 rocket’s launch pad at Space Launch Complex-40. Credit: Google Maps/Ars Technica

SpaceX is in an earlier phase of planning for a Falcon landing pad at historic Launch Complex-39A at NASA’s Kennedy Space Center, just a few miles north of SLC-40. SpaceX uses LC-39A as a launch pad for most Falcon 9 crew launches, all Falcon Heavy missions, and, in the future, flights of the company’s gigantic next-generation rocket, Starship. SpaceX foresees Starship as a replacement for Falcon 9 and Falcon Heavy, but the company’s continuing investment in Falcon-related infrastructure shows the workhorse rocket will stick around for a while.

Lull in Falcon Heavy missions opens window for SpaceX to build new landing pads Read More »

fcc-chair-teams-up-with-ted-cruz-to-block-wi-fi-hotspots-for-schoolkids

FCC chair teams up with Ted Cruz to block Wi-Fi hotspots for schoolkids

“Chairman Carr’s moves today are very unfortunate as they further signal that the Commission is no longer prioritizing closing the digital divide,” Schwartzman said. “In the 21st Century, education doesn’t stop when a student leaves school and today’s actions could lead to many students having a tougher time completing homework assignments because their families lack Internet access.”

Biden FCC expanded school and library program

Under then-Chairwoman Jessica Rosenworcel, the FCC expanded its E-Rate program in 2024 to let schools and libraries use Universal Service funding to lend out Wi-Fi hotspots and services that could be used off-premises. The FCC previously distributed Wi-Fi hotspots and other Internet access technology under pandemic-related spending authorized by Congress in 2021, but that program ended. The new hotspot lending program was supposed to begin this year.

Carr argues that when the Congressionally approved program ended, the FCC lost its authority to fund Wi-Fi hotspots for use outside of schools and libraries. “I dissented from both decisions at the time, and I am now pleased to circulate these two items, which will end the FCC’s illegal funding [of] unsupervised screen time for young kids,” he said.

Under Rosenworcel, the FCC said the Communications Act gives it “broad and flexible authority to establish rules governing the equipment and services that will be supported for eligible schools and libraries, as well as to design the specific mechanisms of support.”

The E-Rate program can continue providing telecom services to schools and libraries despite the hotspot component being axed. E-Rate disbursed about $1.75 billion in 2024, but could spend more based on demand because it has a funding cap of about $5 billion per year. E-Rate and other Universal Service programs are paid for through fees imposed on phone companies, which typically pass the cost on to consumers.

FCC chair teams up with Ted Cruz to block Wi-Fi hotspots for schoolkids Read More »

remarkable’s-newest-e-ink-writing-tablet-is-a-7.3-inch,-$449-handheld-slab

reMarkable’s newest E-Ink writing tablet is a 7.3-inch, $449 handheld slab

Fans of reMarkable’s series of notepad-like note-taking E-Ink tablets have something new to get excited about today: a new version of the devices called the reMarkable Paper Pro Move, which takes the features of a typical reMarkable tablet and puts them in a smaller 7.3-inch device that can be carried one-handed and easily slid into a pocket or bag.

The Paper Pro Move is available to order now and starts at $449 for a version with reMarkable’s standard Marker accessory and no case. Adding a Marker Pro accessory, which includes a built-in eraser and a nicer-to-hold texture, adds another $50. Folio cases for the device range from $69 to $139, or you can order the tablet without one.

Like the full-size reMarkable Paper Pro we reviewed a year ago, the Move uses a Canvas Color E-Ink display to support note-taking and highlighting in multiple colors—according to the spec sheet, it can render 20,000 distinct shades. Both the Paper Pro and the Paper Pro move advertise up to two weeks of battery life, similar 12 ms writing latency, 64GB of storage, a USB-C port for data and charging, Wi-Fi and Bluetooth, and 2GB of RAM. The Pro Move is somewhat thicker (0.26 inches, up from 0.2 inches for the Paper Pro) and uses a dual-core Arm processor instead of a quad-core model. But the Pro Move also weighs less than half as much as the Paper Pro, making it much more portable.

reMarkable’s newest E-Ink writing tablet is a 7.3-inch, $449 handheld slab Read More »

openai-announces-parental-controls-for-chatgpt-after-teen-suicide-lawsuit

OpenAI announces parental controls for ChatGPT after teen suicide lawsuit

On Tuesday, OpenAI announced plans to roll out parental controls for ChatGPT and route sensitive mental health conversations to its simulated reasoning models, following what the company has called “heartbreaking cases” of users experiencing crises while using the AI assistant. The moves come after multiple reported incidents where ChatGPT allegedly failed to intervene appropriately when users expressed suicidal thoughts or experienced mental health episodes.

“This work has already been underway, but we want to proactively preview our plans for the next 120 days, so you won’t need to wait for launches to see where we’re headed,” OpenAI wrote in a blog post published Tuesday. “The work will continue well beyond this period of time, but we’re making a focused effort to launch as many of these improvements as possible this year.”

The planned parental controls represent OpenAI’s most concrete response to concerns about teen safety on the platform so far. Within the next month, OpenAI says, parents will be able to link their accounts with their teens’ ChatGPT accounts (minimum age 13) through email invitations, control how the AI model responds with age-appropriate behavior rules that are on by default, manage which features to disable (including memory and chat history), and receive notifications when the system detects their teen experiencing acute distress.

The parental controls build on existing features like in-app reminders during long sessions that encourage users to take breaks, which OpenAI rolled out for all users in August.

High-profile cases prompt safety changes

OpenAI’s new safety initiative arrives after several high-profile cases drew scrutiny to ChatGPT’s handling of vulnerable users. In August, Matt and Maria Raine filed suit against OpenAI after their 16-year-old son Adam died by suicide following extensive ChatGPT interactions that included 377 messages flagged for self-harm content. According to court documents, ChatGPT mentioned suicide 1,275 times in conversations with Adam—six times more often than the teen himself. Last week, The Wall Street Journal reported that a 56-year-old man killed his mother and himself after ChatGPT reinforced his paranoid delusions rather than challenging them.

To guide these safety improvements, OpenAI is working with what it calls an Expert Council on Well-Being and AI to “shape a clear, evidence-based vision for how AI can support people’s well-being,” according to the company’s blog post. The council will help define and measure well-being, set priorities, and design future safeguards including the parental controls.

OpenAI announces parental controls for ChatGPT after teen suicide lawsuit Read More »